Drugmakers turn to artificial intelligence (AI); new reports of vaccine appointment cancellations or insurance issues; Biden plans to clear Americans’ credit scores of medical debt.
Major pharmaceutical companies, including Amgen, Bayer, and Novartis, are increasingly deploying artificial intelligence (AI) to revolutionize clinical trials, according to Reuters. AI tools, like Amgen's ATOMIC, are streamlining patient recruitment by identifying high-performing clinics and doctors, significantly reducing enrollment times. Moreover, AI is aiding in the design of trials, potentially eliminating the need for placebo groups through the creation of external control arms based on real-world patient data. This AI-driven approach not only expedites drug development but also offers substantial cost savings.
The rollout of the newest COVID-19 vaccines, authorized for individuals 6 months and older, is facing challenges, according to the Associated Press. Some individuals have had to cancel appointments due to insurance companies not yet updating billing codes for the vaccines, while others have seen appointments canceled because of supply issues. Slow shipments and order backlogs have contributed to limited vaccine availability in certain areas. Although Moderna and Pfizer say they have adequate supply, logistical hiccups are affecting the distribution process, causing frustration for those eagerly seeking vaccinations.
The Biden administration has revealed its intentions to develop federal rules that would prevent unpaid medical bills from affecting patients' credit scores, according to Kaiser Health News. This action comes in response to the significant problem of medical debt affecting about 100 million Americans, leading many to take on additional work, lose their homes, and even ration essentials. These new regulations, although expected to face opposition from the medical industry, have garnered robust support from patient and consumer groups who have long advocated for stronger protections against medical debt. While the process to enact these rules may be lengthy, they offer potential relief to those facing the devastating consequences of medical debt on their credit reports and financial lives.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Health Equity and Access Weekly Roundup: April 27, 2024
April 27th 2024Racial disparities in end-of-life care, the role of wellness and faith in minority health, award-winning research on health disparities, societal factors impacting cardiometabolic health, and rising mental health challenges among US youth are all covered this week in the Center on Health Equity and Access.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More